Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors.

ABSTRACT: Here we introduce a first-in-class microRNA-sensitive oncolytic Zika virus (ZIKV) for virotherapy application against central nervous system (CNS) tumors. The described methodology produced two synthetic modified ZIKV strains that are safe in normal cells, including neural stem cells, while preserving brain tropism and oncolytic effects in tumor cells. The microRNA-sensitive ZIKV introduces genetic modifications in two different virus sites: first, in the established 3'UTR region, and secondly, in the ZIKV protein coding sequence, demonstrating for the first time that the miRNA inhibition systems can be functional outside the UTR RNA sites. The total tumor remission in mice bearing human CNS tumors, including metastatic tumor growth, after intraventricular and systemic modified ZIKV admini

SUBMITTER: Novaes GM 

PROVIDER: S-EPMC10861990 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature